Basilea announces CHF 5 million milestone payment from Asahi Kasei Pharma for antifungal Cresemba® (isavuconazole) in Japan

Basilea Pharmaceutica Ltd announced that its license partner Asahi Kasei Pharma has reported the achievement of a milestone related to the launch of Cresemba® in Japan, which triggered a CHF 5 million payment from AKP to Basilea.

Scroll to Top